The earnings call highlighted strong financial and product performance, particularly for IBSRELA, and strategic steps to strengthen the company's leadership and financial flexibility. However, challenges include the departure of a key executive and the impact of losing Medicare as a payer for XPHOZAH. The positive aspects of growth and strategic positioning slightly outweigh the challenges noted.

Company Guidance -

Q3 2025

During the Ardelyx second quarter 2025 earnings call, the company provided several key financial metrics and updates on their product performance. Total revenue for the quarter was $97.7 million, reflecting a 33% year-over-year growth. IBSRELA, a therapy for IBS-C, reported net sales revenue of $65 million, marking an 84% increase compared to the previous year and a 46% quarter-over-quarter growth. The company raised its full-year 2025 net sales revenue guidance for IBSRELA to between $250 million and $260 million, projecting peak sales of over $1 billion. XPHOZAH, another product targeting CKD patients on dialysis, recorded $25 million in net sales revenue, up 7% from the first quarter and 27% when adjusted for a previous reserve release. The gross-to-net deduction for XPHOZAH was approximately 29%, and the overall market response to promotional strategies was positive. Ardelyx strengthened its balance sheet by drawing an additional $50 million of debt and completed its royalty obligation to AstraZeneca. The company anticipates further growth, driven by broad-based patient access and commercial execution, with a focus on maintaining momentum in the second half of 2025.

Strong Revenue Growth

Total revenue for Q2 2025 was $97.7 million, representing a 33% year-over-year increase.

IBSRELA Performance

IBSRELA recorded net sales revenue of $65 million for Q2, up 84% year-over-year and 46% quarter-over-quarter. The company raised full year 2025 net sales revenue guidance for IBSRELA to $250 million to $260 million.

XPHOZAH Sales Increase

XPHOZAH posted net sales revenue of $25 million in Q2, up 7% compared to Q1 2025, and a 27% increase when adjusted for the onetime reserve released in Q1.

Improved Financial Flexibility

The company strengthened its balance sheet by drawing an additional $50 million of debt at a favorable interest rate.

Leadership Expansion

The company appointed new executives to strengthen leadership, including a Chief Business Officer and Chief Patient Officer.

Ardelyx (ARDX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ARDX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-0.06 / -	0	―	―	―
Aug 04, 2025	2025 (Q2)	-0.13 / -0.08	-0.07	-14.29% (>-0.01)	―
May 01, 2025	2025 (Q1)	-0.11 / -0.17	-0.11	-54.55% (-0.06)	―
Feb 20, 2025	2024 (Q4)	<0.01 / 0.02	-0.12	116.67% (+0.14)	―
Oct 31, 2024	2024 (Q3)	-0.05 / 0.00	0.03	―	―
Aug 01, 2024	2024 (Q2)	-0.11 / -0.07	-0.08	12.50% (<+0.01)	―
May 02, 2024	2024 (Q1)	-0.15 / -0.11	-0.13	15.38% (+0.02)	―
Feb 22, 2024	2023 (Q4)	-0.10 / -0.12	0.06	-300.00% (-0.18)	―
Oct 31, 2023	2023 (Q3)	-0.11 / 0.03	-0.14	121.43% (+0.17)	―
Aug 02, 2023	2023 (Q2)	-0.12 / -0.08	-0.19	57.89% (+0.11)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ARDX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 04, 2025	$4.39	$5.13	+16.86%
May 01, 2025	$5.47	$4.13	-24.50%
Feb 20, 2025	$6.36	$5.72	-10.06%
Oct 31, 2024	$5.87	$6.09	+3.75%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.